Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size, Status and Forecast 2024-2031

Report ID: 934207 | Published Date: Jan 2025 | No. of Page: 98 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Wet AMD
        1.2.3 Dry AMD
    1.3 Market by Application
        1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Research Institute
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Perspective (2016-2027)
    2.2 Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Regions
        2.2.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Share by Regions (2016-2021)
        2.2.3 Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Regions (2022-2027)
    2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Dynamic
        2.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
        2.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
        2.3.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
        2.3.4 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue
        3.1.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue (2016-2021)
        3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2016-2021)
    3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Age-Related Macular Degeneration (AMD) Therapeutics Revenue
    3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio
        3.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2020
    3.5 Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Area Served
    3.6 Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service
    3.7 Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Type
    4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Type (2016-2021)
    4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Application
    5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Application (2016-2021)
    5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
    6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
        6.2.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
        6.2.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
        6.2.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
    6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
        6.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
        6.3.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
        6.3.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
    6.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
        6.4.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
        6.4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
    7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
        7.2.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
        7.2.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
        7.2.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
    7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
        7.3.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
        7.3.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
        7.3.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
    7.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
        7.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
        7.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
    8.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
    9.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
        9.2.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
        9.2.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
        9.2.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
    9.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
        9.3.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
        9.3.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
        9.3.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
    9.4 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
        9.4.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
        9.4.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
    10.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Amgen Inc.
        11.1.1 Amgen Inc. Company Details
        11.1.2 Amgen Inc. Business Overview
        11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
        11.1.4 Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
        11.1.5 Amgen Inc. Recent Development
    11.2 Bausch Health Companies, Inc.
        11.2.1 Bausch Health Companies, Inc. Company Details
        11.2.2 Bausch Health Companies, Inc. Business Overview
        11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
        11.2.4 Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
        11.2.5 Bausch Health Companies, Inc. Recent Development
    11.3 F. Hoffmann-La Roche Ltd.
        11.3.1 F. Hoffmann-La Roche Ltd. Company Details
        11.3.2 F. Hoffmann-La Roche Ltd. Business Overview
        11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
        11.3.4 F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
        11.3.5 F. Hoffmann-La Roche Ltd. Recent Development
    11.4 Novartis AG
        11.4.1 Novartis AG Company Details
        11.4.2 Novartis AG Business Overview
        11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Introduction
        11.4.4 Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
        11.4.5 Novartis AG Recent Development
    11.5 Regeneron Pharmaceuticals Inc.
        11.5.1 Regeneron Pharmaceuticals Inc. Company Details
        11.5.2 Regeneron Pharmaceuticals Inc. Business Overview
        11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
        11.5.4 Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
        11.5.5 Regeneron Pharmaceuticals Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Wet AMD
    Table 3. Key Players of Dry AMD
    Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2016-2021)
    Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2022-2027)
    Table 10. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
    Table 11. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
    Table 12. Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
    Table 13. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
    Table 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players (2016-2021)
    Table 16. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2020)
    Table 17. Ranking of Global Top Age-Related Macular Degeneration (AMD) Therapeutics Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service
    Table 21. Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2016-2021)
    Table 25. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2016-2021)
    Table 29. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Amgen Inc. Company Details
    Table 62. Amgen Inc. Business Overview
    Table 63. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
    Table 64. Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
    Table 65. Amgen Inc. Recent Development
    Table 66. Bausch Health Companies, Inc. Company Details
    Table 67. Bausch Health Companies, Inc. Business Overview
    Table 68. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
    Table 69. Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
    Table 70. Bausch Health Companies, Inc. Recent Development
    Table 71. F. Hoffmann-La Roche Ltd. Company Details
    Table 72. F. Hoffmann-La Roche Ltd. Business Overview
    Table 73. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product
    Table 74. F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
    Table 75. F. Hoffmann-La Roche Ltd. Recent Development
    Table 76. Novartis AG Company Details
    Table 77. Novartis AG Business Overview
    Table 78. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product
    Table 79. Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
    Table 80. Novartis AG Recent Development
    Table 81. Regeneron Pharmaceuticals Inc. Company Details
    Table 82. Regeneron Pharmaceuticals Inc. Business Overview
    Table 83. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
    Table 84. Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
    Table 85. Regeneron Pharmaceuticals Inc. Recent Development
    Table 86. Research Programs/Design for This Report
    Table 87. Key Data Information from Secondary Sources
    Table 88. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type: 2020 VS 2027
    Figure 2. Wet AMD Features
    Figure 3. Dry AMD Features
    Figure 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2020 VS 2027
    Figure 5. Hospital Case Studies
    Figure 6. Clinic Case Studies
    Figure 7. Research Institute Case Studies
    Figure 8. Other Case Studies
    Figure 9. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered
    Figure 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions: 2020 VS 2027
    Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2022-2027)
    Figure 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players in 2020
    Figure 15. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2020
    Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2016-2021)
    Figure 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2022-2027)
    Figure 19. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
    Figure 21. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
    Figure 22. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
    Figure 23. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
    Figure 27. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
    Figure 28. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
    Figure 29. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region (2016-2027)
    Figure 39. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
    Figure 47. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
    Figure 48. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
    Figure 49. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
    Figure 55. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Amgen Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
    Figure 59. Bausch Health Companies, Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
    Figure 60. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
    Figure 61. Novartis AG Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
    Figure 62. Regeneron Pharmaceuticals Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Frequently Asked Questions
Age-Related Macular Degeneration (AMD) Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Age-Related Macular Degeneration (AMD) Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Age-Related Macular Degeneration (AMD) Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports